Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma

Efficacy of temsirolimus in metastatic chromophobe renal cell carcinoma

BACKGROUND Renal cell carcinoma (RCC) is a histopathologically and molecularly heterogeneous disease with the chromophobe subtype (chRCC) accounting for approximately 5% of all cases. The median overall survival of advanced RCC has improved significantly since the advent of tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors. However, high-quality evidence for the use...

Sarcomatoid Transrormation of Chromophobe Renal Cell Carcinoma

Temsirolimus in VEGF-refractory metastatic renal cell carcinoma.

BACKGROUND Temsirolimus is an i.v. administered inhibitor of mammalian target of rapamycin with activity in the first-line setting in poor-prognosis patients with metastatic renal cell carcinoma (RCC). The efficacy of this agent after failure of prior inhibitors of vascular endothelial growth factor (VEGF) is unknown. METHODS a retrospective review of patients with metastatic RCC treated at t...

Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma.

PURPOSE Sunitinib and sorafenib are novel tyrosine kinase inhibitors (TKIs) that have shown significant clinical activity in metastatic clear cell renal cell carcinoma (RCC). The activity of sunitinib and sorafenib in non-clear cell histologies has not been evaluated. PATIENTS AND METHODS Clinical features at study entry and treatment outcomes were evaluated in patients with metastatic papill...

Genomic landscape and evolution of metastatic chromophobe renal cell carcinoma.

Chromophobe renal cell carcinoma (chRCC) typically shows ~7 chromosome losses (1, 2, 6, 10, 13, 17, and 21) and ~31 exonic somatic mutations, yet carries ~5%-10% metastatic incidence. Since extensive chromosomal losses can generate proteotoxic stress and compromise cellular proliferation, it is intriguing how chRCC, a tumor with extensive chromosome losses and a low number of somatic mutations,...